Ozempic's kidney approval: what the FLOW trial actually proved

What did @cp24breakingnews actually say?

The claim is straightforward: Health Canada approved Ozempic to slow kidney decline in Type 2 diabetes patients. The creator cited a 24 percent reduction in kidney deterioration or failure compared to placebo, referencing a peer-reviewed trial published in the New England Journal of Medicine. They also stated that between 30 and 50 percent of people with Type 2 diabetes develop chronic kidney disease.

This is a news report, not a medical opinion, and the creator largely stuck to the facts without inflating what the data actually showed. The 24 percent figure is a relative risk reduction, not an absolute one, and the video does not clarify that distinction. That omission matters when communicating risk to a general audience, but it is not a fabrication. The core regulatory claim, that Health Canada approved this indication, is accurate and verifiable through Health Canada's public drug product database.

Does the science back this up?

Yes, with some important context the video leaves out. The FLOW trial (Perkovic et al., 2024, New England Journal of Medicine) is the study being referenced, and it is legitimate, large-scale, and peer-reviewed. The 24 percent relative risk reduction for kidney failure or significant deterioration is consistent with what was published.

The trial enrolled over 3,500 patients with Type 2 diabetes and chronic kidney disease across more than 28 countries. The primary composite endpoint included a sustained 50 percent or greater decline in eGFR, kidney failure, or death from kidney or cardiovascular causes. Semaglutide 1.0 mg weekly reduced that composite endpoint by 24 percent relative to placebo. The absolute risk reduction was approximately 5 percentage points over a median follow-up of around 3.4 years, which is clinically meaningful but sounds less dramatic than the relative figure. The video never mentions that distinction. The study was stopped early due to clear benefit, which regulators and journal editors noted as a limitation worth flagging. Still, the data quality here is solid. This is not a small, industry-funded pilot study with soft endpoints.

What did they get wrong (or right)?

They got the regulatory fact right, the trial right, the journal right, and the general direction of the statistic right. Credit where it is due. The 30 to 50 percent prevalence figure for chronic kidney disease in Type 2 diabetes is also within the accepted range, consistent with estimates from the National Kidney Foundation and multiple epidemiological reviews.

Where the video falls short is in presenting the 24 percent figure without clarifying it is a relative risk reduction. For a TikTok audience, that number sounds enormous. The absolute risk reduction of roughly 5 percentage points over three-plus years is still meaningful clinically, but it is a different kind of meaningful. The creator also does not mention that this approval is specifically for people who already have chronic kidney disease alongside Type 2 diabetes, not for all Ozempic users. That is a real distinction. This is not a blanket kidney protection approval for anyone on semaglutide. The framing could lead viewers to assume broader benefit than what the approval actually covers.

What should you actually know?

If you have Type 2 diabetes and have already been diagnosed with chronic kidney disease, this approval is genuinely relevant to your care. Semaglutide's kidney benefits appear to go beyond blood sugar control alone, which is what makes the FLOW trial interesting. Researchers observed kidney-protective effects that were not fully explained by glycemic improvements, suggesting a more direct mechanism, possibly involving reduced inflammation and lower intraglomerular pressure.

That said, Ozempic is not a cure for kidney disease. It reduces the risk of further decline, which is a meaningful but limited claim. Patients with advanced kidney disease, particularly those near or on dialysis, were not well-represented in FLOW, so the data does not extend confidently to that population. If you are managing Type 2 diabetes and kidney disease, this is a conversation to have with your prescribing physician. The approval expands the evidence base for using semaglutide in this population, but your individual kidney function, cardiovascular history, and medication interactions all factor into whether it is appropriate for you specifically.

• The FLOW trial ran for a median of approximately 3.4 years across over 3,500 participants.
• Semaglutide's kidney benefits in the trial were not fully explained by blood sugar reduction alone.
• Health Canada's approval is specific to patients who have both Type 2 diabetes and chronic kidney disease.